Inventor · disambiguated record
Joanne Wang
Also filed as: WANG JOANNE
26 granted patents·14 pending applications·252 citations·filing 2009–2023
97Inventor score
Top patents by PatentIndex Score
40 records- 0198US11332518B2Immuno-based botulinum toxin serotype A activity assaysALLERGAN INC·Filed 2021·Granted May 17, 2022·7 cites·30 claims
- 0297US11261240B2Immuno-based botulinum toxin serotype A activity assaysALLERGAN INC·Filed 2020·Granted Mar 1, 2022·7 cites·16 claims
- 0397US8198034B2Immuno-based botulinum toxin serotype A activity assaysFERNANDEZ-SALAS ESTER·Filed 2009·Granted Jun 12, 2012·63 cites·25 claims
- 0495US10703806B2Immuno-based botulinum toxin serotype A activity assaysALLERGAN INC·Filed 2017·Granted Jul 7, 2020·10 cites·4 claims
- 0595US8455247B2Cells useful for immuno-based botulinum toxin serotype A activity assaysZHU HONG·Filed 2011·Granted Jun 4, 2013·10 cites·5 claims
- 0695US8455213B2Cells useful for immuno-based botulinum toxin serotype A activity assaysZHU HONG·Filed 2011·Granted Jun 4, 2013·14 cites·5 claims
- 0795US8361789B2Cells useful for immuno-based Botulinum toxin serotype A activity assaysALLERGAN INC·Filed 2010·Granted Jan 29, 2013·13 cites·5 claims
- 0894US9249216B2Immuno-based botulinum toxin serotype A activity assaysFERNANDEZ-SALAS ESTER·Filed 2012·Granted Feb 2, 2016·23 cites·4 claims
- 0994US8618261B2Immuno-based botulinum toxin serotype A activity assaysESTER FERNANDEZ-SALAS·Filed 2010·Granted Dec 31, 2013·44 cites·2 claims
- 1092US8507271B2Cells useful for immuno-based botulinum toxin serotype A activity assaysZHU HONG·Filed 2011·Granted Aug 13, 2013·6 cites·5 claims
- 1192US8501469B2Cells useful for immuno-based botulinum toxin serotype A activity assaysZHU HONG·Filed 2011·Granted Aug 6, 2013·6 cites·5 claims
- 1292US8455203B2Immuno-based retargeted endopeptidase activity assaysWANG JOANNE·Filed 2010·Granted Jun 4, 2013·23 cites·1 claims
- 1391US10345306B2Immuno-based retargeted endopeptidase activity assaysALLERGAN INC·Filed 2017·Granted Jul 9, 2019·4 cites·17 claims
- 1489US8691566B1Cells useful for immuno-based botulinum toxin serotype a activity assaysZHU HONG·Filed 2011·Granted Apr 8, 2014·4 cites·5 claims
- 1589US8455248B2Cells useful for immuno-based Botulinum toxin serotype A activity assaysZHU HONG·Filed 2011·Granted Jun 4, 2013·4 cites·5 claims
- 1688US9651553B2Immuno-based retargeted endopeptidase activity assaysALLERGAN INC·Filed 2015·Granted May 16, 2017·3 cites·4 claims
- 1788US8476068B2Cells useful for immuno-based botulinum toxin serotype A activity assaysZHU HONG·Filed 2011·Granted Jul 2, 2013·3 cites·5 claims
- 1887US10900967B2Immuno-based retargeted endopeptidase activity assaysALLERGAN INC·Filed 2019·Granted Jan 26, 2021·2 cites·10 claims
- 1987US2024272160A1Immuno-based retargeted endopeptidase activity assaysALLERGAN INC·Filed 2023·Application pending·0 cites
- 2086US9625447B2Cells useful for immuno-based botulinum toxin serotype A activity assaysZHU HONG·Filed 2011·Granted Apr 18, 2017·2 cites·5 claims
- 2186US2023323290A1Cells useful for immuno-based botulinum toxin serotype a activity assaysALLERGAN INC·Filed 2022·Application pending·0 cites
- 2285US2023279083A1Immuno-based botulinum toxin serotype a activity assaysALLERGAN INC·Filed 2022·Application pending·0 cites
- 2385US2023235031A1Immuno-based botulinum toxin serotype a activity assaysALLERGAN INC·Filed 2022·Application pending·0 cites
- 2482US2022144925A1Immuno-based botulinum toxin serotype a activity assaysALLERGAN INC·Filed 2022·Application pending·0 cites
- 2581US8476069B2Cells useful for immuno-based botulinum toxin serotype A activity assaysZHU HONG·Filed 2011·Granted Jul 2, 2013·1 cites·5 claims
- 2679US2021163887A1Cells useful for immuno-based botulinum toxin serotype a activity assaysALLERGAN INC·Filed 2021·Application pending·0 cites
- 2775US2021172952A1Immuno-based retargeted endopeptidase activity assaysALLERGAN INC·Filed 2021·Application pending·0 cites
- 2874US10451621B2Highly sensitive cell-based assay to detect the presence of active botulinum neurotoxin serotype-AALLERGAN INC·Filed 2012·Granted Oct 22, 2019·3 cites·12 claims
- 2974US2020392212A1Immuno-based botulinum toxin serotype a activity assaysALLERGAN INC·Filed 2020·Application pending·0 cites
- 3074US2020369749A1Immuno-based botulinum toxin serotype a activity assaysALLERGAN INC·Filed 2020·Application pending·0 cites
- 3173US2023302103A1Botulinum neurotoxin for treatment of disorders associated with melanocyte hyperactivity and/or excess melaninALLERGAN INC·Filed 2022·Application pending·0 cites
- 3271US10912823B2Botulinum neurotoxin for treatment of disorders associated with melanocyte hyperactivity and/or excess melaninALLERGAN INC·Filed 2018·Granted Feb 9, 2021·0 cites·20 claims
- 3371US2017218334A1Cells Useful for Immuno-Based Botulinum Toxin Serotype A Activity AssaysALLERGAN INC·Filed 2017·Application pending·0 cites
- 3467US8663983B2Cells useful for immuno-based botulinum toxin serotype A activity assaysZHU HONG·Filed 2011·Granted Mar 4, 2014·0 cites·5 claims
- 3567US8663982B2Cells useful for immuno-based botulinum toxin serotype A activity assaysZHU HONG·Filed 2011·Granted Mar 4, 2014·0 cites·5 claims
- 3667US8603812B2Cells useful for immuno-based botulinum toxin serotype A activity assaysZHU HONG·Filed 2011·Granted Dec 10, 2013·0 cites·5 claims
- 3765US8603813B2Cells useful for immuno-based botulinum toxin serotype A activity assaysZHU HONG·Filed 2011·Granted Dec 10, 2013·0 cites·5 claims
- 3865US2021162027A1Botulinum neurotoxin for treatment of disorders associated with melanocyte hyperactivity and/or excess melaninALLERGAN INC·Filed 2021·Application pending·0 cites
- 3964US2013267010A1Immuno-Based Retargeted Endopeptidase Activity AssaysALLERGAN INC·Filed 2013·Application pending·0 cites
- 4064US2013040368A1Immuno-based botulinum toxin serotype a activity assaysALLERGAN INC·Filed 2012·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Joanne Wang files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →